Literature DB >> 27998559

Nivolumab plus interferon-γ in the treatment of intractable mucormycosis.

David Grimaldi1, Olivier Pradier2, Richard S Hotchkiss3, Jean-Louis Vincent4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27998559     DOI： 10.1016/S1473-3099(16)30541-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  42 in total

Review 1.  Immune therapy in sepsis: Are we ready to try again?

Authors:  Roger Davies; Kieran O'Dea; Anthony Gordon
Journal:  J Intensive Care Soc       Date:  2018-04-04

2.  On the verge of using an immune toolbox in the intensive care unit?

Authors:  Frédéric Pène; Jean-Louis Vincent; Ignacio Martin-Loeches
Journal:  Intensive Care Med       Date:  2017-05-11       Impact factor: 17.440

3.  Fungal immunology in clinical practice: Magical realism or practical reality?

Authors:  Christina C Chang; Stuart M Levitz
Journal:  Med Mycol       Date:  2019-06-01       Impact factor: 4.076

Review 4.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

Review 5.  Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors.

Authors:  Xin Li; Susanna Kp Lau; Patrick Cy Woo
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-08

Review 6.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 7.  Advances in the understanding and treatment of sepsis-induced immunosuppression.

Authors:  Fabienne Venet; Guillaume Monneret
Journal:  Nat Rev Nephrol       Date:  2017-12-11       Impact factor: 28.314

Review 8.  Modulating host immune responses to fight invasive fungal infections.

Authors:  James E Scriven; Mark W Tenforde; Stuart M Levitz; Joseph N Jarvis
Journal:  Curr Opin Microbiol       Date:  2017-11-15       Impact factor: 7.934

9.  Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab.

Authors:  Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Elliott D Crouser; Greg S Martin; Timothy Albertson; Raquel R Bartz; Scott C Brakenridge; Matthew J Delano; Pauline K Park; Michael W Donnino; Mark Tidswell; Florian B Mayr; Derek C Angus; Craig M Coopersmith; Lyle L Moldawer; Ian M Catlett; Ihab G Girgis; June Ye; Dennis M Grasela
Journal:  Intensive Care Med       Date:  2019-10-01       Impact factor: 17.440

10.  Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents.

Authors:  Marilia Bernardes; Tobias M Hohl
Journal:  Curr Clin Microbiol Rep       Date:  2020-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.